Technology
Health
Biotechnology

IMV

$3.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.23 (-5.75%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell IMV and other stocks, options, ETFs, and crypto commission-free!

About

IMV, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Read More The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.

Employees
Headquarters
Dartmouth, Nova Scotia
Founded
2000
Market Cap
170.05M
Price-Earnings Ratio
Dividend Yield
Average Volume
15.07K
High Today
$3.91
Low Today
$3.77
Open Price
$3.90
Volume
7.42K
52 Week High
$7.21
52 Week Low
$2.90

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2018 IPO

News

Financial PostMay 10

IMV Announces Annual and Special Meeting of Shareholders Voting Results

DARTMOUTH, Nova Scotia — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company (or the ”Corporation”), today announced the voting results from its Annual and Special Meeting of Shareholders held on Thursday May 9, 2019. Based on the proxies received and the votes on a show of hands, all resolutions were accepted including the election of Directors for whom details of the votes are as follows; Name of Nominee Votes cast FOR % of votes cast FOR Julia Gregory 26,089,068 99.90% James H. Ha...

11
Yahoo FinanceMay 9

IMV Inc. Announces Q1 2019 Financial Results and Clinical Program Advances

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, today released its financial and operational results for the first quarter ended March 31, 2019. “The DPX-Survivac program continues to be a major value-driver for IMV, with its unique mechanism of action providing significant clinical differentiation and, potentially, a much-needed innovation for hard-to-treat cancers,” said Frederic Ors, IMV's Chief Executive Officer. “Highlights of our ov...

12
Markets InsiderMay 8

IMV Joins World Ovarian Cancer Coalition and Ovarian Cancer Canada in Supporting Ovarian Cancer Day 2019

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today joins with World Ovarian Cancer Coalition and Ovarian Cancer Canada in recognizing World Ovarian Cancer Day (WOCD). This initiative aims to raise awareness of, and bring hope to, the global challenges faced by women living with a diagnosis of ovarian cancer. "Ovarian cancer remains one of the most underserved, difficult-to-treat forms of the disease,” said Frederic Ors, Chief Executive Officer at IMV Inc. "IMV is committe...

6
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.